R

Regulus Therapeutics

D
RGLS
USD
0
(0%)
Market Closed
14,624.00
Volume
-0.8
EPS
-
Div Yield
-1.233333
P/E
96,889,496.48
Market Cap
Today
-1.9868%
1 Week
0.680%
1 Month
-13.953%
6 Months
-33.632%
12 Months
4.225%
Year To Date
17.460%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
S
SRPT
-7.62
(-5.9531%)
USD
F
FOLD
-0.27
(-2.4043%)
USD
X
XLRN
(%)
USD
A
AXSM
-0.28
(-0.3079%)
USD
V
VKTX
2.97
(4.5075%)
USD
D
DVAX
-0.29
(-2.3577%)
USD
I
IONS
-0.62
(-1.5869%)
USD
A
ARWR
0.055
(0.2579%)
USD
C
CRSP
1.15
(2.2656%)
USD
E
EDIT
-0.11
(-3.3537%)
USD

Title:
Regulus Therapeutics

Sector:
Healthcare
Industry:
Biotechnology
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Do you need help or have a question?
Contact Us